Invention Grant
- Patent Title: Glycoengineered antibody drug conjugates
-
Application No.: US14878444Application Date: 2015-10-08
-
Publication No.: US10064952B2Publication Date: 2018-09-04
- Inventor: Luis Z. Avila , Qun Zhou
- Applicant: Genzyme Corporation
- Applicant Address: US MA Cambridge
- Assignee: GENZYME CORPORATION
- Current Assignee: GENZYME CORPORATION
- Current Assignee Address: US MA Cambridge
- Agency: Lathrop Gage LLP
- Agent James H. Velema, Esq.
- Main IPC: A61K47/48
- IPC: A61K47/48 ; C07K16/28 ; C07K16/32 ; C07K16/40 ; A61K47/68 ; A61K47/54 ; A61K39/00

Abstract:
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
Public/Granted literature
- US20160136299A1 GLYCOENGINEERED ANTIBODY DRUG CONJUGATES Public/Granted day:2016-05-19
Information query